Patents by Inventor Matthew Cheeseman

Matthew Cheeseman has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Mineral compositions
    Patent number: 11840455
    Abstract: A composition comprising at least one inorganic particulate material such as calcium carbonate, use of a said composition in a barrier coating composition or in a paper coating composition, a method for making said composition, a method for making a paper coating composition and a method for making a coated product.
    Type: Grant
    Filed: June 30, 2016
    Date of Patent: December 12, 2023
    Assignee: ImerTech SAS
    Inventors: Matthew Cheeseman, Janet Preston, Graham M. Pring
  • Bimodal precipitated calcium carbonate slurries suitable for paper and board applications, methods for making the same and their uses
    Patent number: 11820667
    Abstract: The present application relates to aqueous slurries comprising precipitated calcium carbonates having a bimodal particle size distribution with a first maximum in particle size distribution and a second maximum in particle size distribution, as well as methods for making them and their uses.
    Type: Grant
    Filed: February 20, 2019
    Date of Patent: November 21, 2023
    Assignee: Imertech SAS
    Inventors: Nigel V. Jarvis, Graham M. Pring, Desmond Charles Payton, Andrew Findlay, Matthew Cheeseman
  • Fused 1,4-dihydrodioxin derivatives as inhibitors of heat shock transcription factor I
    Patent number: 11124501
    Abstract: The present invention relates to compounds of formula I as defined herein. The compounds of the present invention are inhibitors of heat shock factor 1 (HSF1). In particular, the present invention relates to the use of these compounds as therapeutic agents for the treatment and/or prevention of proliferative diseases, such as cancer. The present invention also relates to processes for the preparation of these compounds, and to pharmaceutical compositions comprising them.
    Type: Grant
    Filed: December 6, 2018
    Date of Patent: September 21, 2021
    Assignee: CANCER RESEARCH TECHNOLOGY LIMITED
    Inventors: Keith Jones, Carl Rye, Nicola Chessum, Matthew Cheeseman, Adele E. Pasqua, Kurt G. Pike, Paul F. Faulder
  • BIMODAL PRECIPITATED CALCIUM CARBONATE SLURRIES SUITABLE FOR PAPER AND BOARD APPLICATIONS, METHODS FOR MAKING THE SAME AND THEIR USES
    Publication number: 20210094840
    Abstract: The present application relates to aqueous slurries comprising precipitated calcium carbonates having a bimodal particle size distribution with a first maximum in particle size distribution and a second maximum in particle size distribution, as well as methods for making them and their uses.
    Type: Application
    Filed: February 20, 2019
    Publication date: April 1, 2021
    Inventors: Nigel V. JARVIS, Graham M. PRING, Desmond Charles PAYTON, Andrew FINDLAY, Matthew CHEESEMAN
  • Quinoline derivatives as inhibitors of heat shock factor 1 pathway activity
    Patent number: 10647678
    Abstract: The present invention relates to compounds of formula I wherein R, R4 and Q are each as defined herein. The compounds of the present invention are inhibitors of heat shock factor 1 pathway (HSF1 pathway). In particular, the present invention relates to the use of these compounds as therapeutic agents for the treatment and/or prevention of proliferative diseases, such as cancer. The present invention also relates to processes for the preparation of these compounds, and to pharmaceutical compositions comprising them.
    Type: Grant
    Filed: April 1, 2016
    Date of Patent: May 12, 2020
    Assignee: Cancer Research Technology Limited
    Inventors: Keith Jones, Matthew Cheeseman, Nicola Chessum, Elisa Pasqua, Lindsay Evans, Michael Tucker, Birgit Wilding, Ngai Yi Mok
  • INHIBITOR COMPOUNDS
    Publication number: 20190106413
    Abstract: The present invention relates to compounds of formula I as defined herein. The compounds of the present invention are inhibitors of heat shock factor 1 (HSF1). In particular, the present invention relates to the use of these compounds as therapeutic agents for the treatment and/or prevention of proliferative diseases, such as cancer. The present invention also relates to processes for the preparation of these compounds, and to pharmaceutical compositions comprising them.
    Type: Application
    Filed: December 6, 2018
    Publication date: April 11, 2019
    Inventors: Keith Jones, Carl Rye, Nicola Chessum, Matthew Cheeseman, Adele E, Pasqua, Kurt G, Pike, Paul F. Faulder
  • Fused 1,4-dihydrodioxin derivatives as inhibitors of heat shock transcription factor I
    Patent number: 10189821
    Abstract: The present invention relates to compounds of formula I as defined herein. The compounds of the present invention are inhibitors of heat shock factor 1 (HSF1). In particular, the present invention relates to the use of these compounds as therapeutic agents for the treatment and/or prevention of proliferative diseases, such as cancer. The present invention also relates to processes for the preparation of these compounds, and to pharmaceutical compositions comprising them.
    Type: Grant
    Filed: October 24, 2016
    Date of Patent: January 29, 2019
    Assignee: Cancer Research Technology Limited
    Inventors: Keith Jones, Carl Rye, Nicola Chessum, Matthew Cheeseman, Adele E. Pasqua, Kurt G. Pike, Paul F. Faulder
  • MINERAL COMPOSITIONS
    Publication number: 20180186652
    Abstract: A composition comprising at least one inorganic particulate material such as calcium carbonate, use of a said composition in a barrier coating composition or in a paper coating composition, a method for making said composition, a method for making a paper coating composition and a method for making a coated product.
    Type: Application
    Filed: June 30, 2016
    Publication date: July 5, 2018
    Inventors: Matthew CHEESEMAN, Janet PRESTON, Graham M. PRING
  • QUINOLINE DERIVATIVES AS INHIBITORS OF HEAT SHOCK FACTOR 1 PATHWAY ACTIVITY
    Publication number: 20180093955
    Abstract: The present invention relates to compounds of formula I wherein R, R4 and Q are each as defined herein. The compounds of the present invention are inhibitors of heat shock factor 1 pathway (HSF1 pathway). In particular, the present invention relates to the use of these compounds as therapeutic agents for the treatment and/or prevention of proliferative diseases, such as cancer. The present invention also relates to processes for the preparation of these compounds, and to pharmaceutical compositions comprising them.
    Type: Application
    Filed: April 1, 2016
    Publication date: April 5, 2018
    Inventors: Keith Jones, Matthew Cheeseman, Nicola Chessum, Elise Pasqua, Lindsay Evans, Michael Tucker, Birgit Wilding, Ngal Yi Mok
  • Fused 1,4-dihydrodioxin derivatives as inhibitors of heat shock transcription factor 1
    Patent number: 9701664
    Abstract: The present invention relates to compounds of formula I as defined herein. The compounds of the present invention are inhibitors of heat shock factor 1 (HSF1). In particular, the present invention relates to the use of these compounds as therapeutic agents for the treatment and/or prevention of proliferative diseases, such as cancer. The present invention also relates to processes for the preparation of these compounds, and to pharmaceutical compositions comprising them.
    Type: Grant
    Filed: October 3, 2014
    Date of Patent: July 11, 2017
    Assignee: CANCER RESEARCH TECHNOLOGY LIMITED
    Inventors: Keith Jones, Carl Rye, Nicola Chessum, Matthew Cheeseman, Adele E. Pasqua, Kurt G. Pike, Paul F. Faulder
  • FUSED 1,4-DIHYDRODIOXIN DERIVATIVES AS INHIBITORS OF HEAT SHOCK TRANSCRIPTION FACTOR I
    Publication number: 20170037036
    Abstract: The present invention relates to compounds of formula I as defined herein. The compounds of the present invention are inhibitors of heat shock factor 1 (HSF1). In particular, the present invention relates to the use of these compounds as therapeutic agents for the treatment and/or prevention of proliferative diseases, such as cancer. The present invention also relates to processes for the preparation of these compounds, and to pharmaceutical compositions comprising them.
    Type: Application
    Filed: October 24, 2016
    Publication date: February 9, 2017
    Inventors: Keith Jones, Carl Rye, Nicola Chessum, Matthew Cheeseman, Adele E. Pasqua, Kurt G. Pike, Paul F. Faulder
  • FUSED 1,4-DIHYDRODIOXIN DERIVATIVES AS INHIBITORS OF HEAT SHOCK TRANSCRIPTION FACTOR 1
    Publication number: 20160289216
    Abstract: The present invention relates to compounds of formula I as defined herein. The compounds of the present invention are inhibitors of heat shock factor 1 (HSF1). In particular, the present invention relates to the use of these compounds as therapeutic agents for the treatment and/or prevention of proliferative diseases, such as cancer. The present invention also relates to processes for the preparation of these compounds, and to pharmaceutical compositions comprising them.
    Type: Application
    Filed: October 3, 2014
    Publication date: October 6, 2016
    Inventors: Keith Jones, Carl Rye, Nicola Chessum, Matthew Cheeseman, Adele E. Pasqua, Kurt G. Pike, Paul F. Faulder